RDY (RDY) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving RDY (RDY) right now is Biosimilars ramp: Dr. Revenue (FY26) is ~$4.0B. If that keeps playing out, the setup is favourable; the risk to it is the loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. No one can predict where RDY trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive RDY (RDY) higher?
1. Biosimilars ramp
Dr. Reddy's is building a biosimilar franchise to offset the small-molecule generic squeeze, with denosumab launched in the EU, rituximab approved in Canada in February 2026, and US biosimilar entries targeted for 2026-2027. Biosimilars carry higher barriers to entry and longer competitive runways than plain generics, which could support more durable margins if launches land on schedule.
2. GLP-1 / semaglutide opportunity
The company was first to market generic semaglutide injection in Canada (launched May 2026) and launched it in India under the brand Obeda on day one of loss of exclusivity, plus received authorization for semaglutide tablets in India. GLP-1 weight-loss and diabetes demand is very large, and early-mover generic positioning in markets where exclusivity has lapsed is a potential multi-year growth lever.
3. Consumer health and Nicotinell
Dr. Reddy's acquired Haleon's ex-US nicotine-replacement-therapy business (Nicotinell and related brands) for roughly 500 million pounds (about $633 million), adding a branded consumer-health revenue stream generating around 217 million pounds in annual sales. This diversifies the mix away from volatile US generics toward steadier branded OTC cash flows.
4. Diversified geographic base
Beyond the US, the company earns meaningful revenue in India, Russia and CIS, Europe, and other emerging markets, which cushions US pricing pressure. A broad API and formulations manufacturing footprint gives it vertical integration and cost control across its portfolio.
What could weigh on RDY?
The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. US generic drug pricing is chronically deflationary and highly competitive, so new launches must run fast just to stand still. Biosimilar and GLP-1 ambitions face regulatory, manufacturing, and competitive execution risk, and any US FDA inspection or compliance issue at a plant could disrupt supply. As an ADR, US investors also carry currency (rupee/dollar) and India-specific regulatory and disclosure exposure. Shelf-stock-adjustment and price-reduction charges (a roughly $50 million revenue reduction on lenalidomide in Q4 FY26) show how quickly pricing dynamics can hit reported results.
Where RDY trades today
A forecast starts from where the stock actually is. These are RDY's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for RDY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a RDY forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the RDY guide and whether RDY is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the RDY outlook
The bottom line: what is driving RDY (RDY) is Biosimilars ramp, with revenue (fy26) at ~$4.0B. If that keeps playing out the setup is favourable; the risk is the loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. No one can predict the price, so treat any RDY forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around RDY with Walnut
Use RDY as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for RDY (RDY)?
+
No one can reliably predict where RDY will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push RDY higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive RDY higher?
+
The main growth drivers are Biosimilars ramp; GLP-1 / semaglutide opportunity; Consumer health and Nicotinell. Whether they play out is the real question, not a guaranteed path.
What are the risks to RDY?
+
The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. US generic drug pricing is chronically deflationary and highly competitive, so new launches must run fast just to stand still. Biosimilar and GLP-1 ambitions face regulatory, manufacturing, and competitive execution risk, and any US FDA inspection or compliance issue at a plant could disrupt supply. As an ADR, US investors also carry currency (rupee/dollar) and India-specific regulatory and disclosure exposure. Shelf-stock-adjustment and price-reduction charges (a roughly $50 million revenue reduction on lenalidomide in Q4 FY26) show how quickly pricing dynamics can hit reported results.
Will RDY stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. RDY's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is RDY a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the RDY "is it a buy?" page for a framework. Walnut is not an investment adviser.
What were Dr. Reddy's FY2026 results?
+
FY26 revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, with EBITDA margin near 22.8%. However, Q4 FY26 revenue fell about 11.6% year over year and margins compressed sharply as the Revlimid exclusivity ended.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.